| SC 13G/A | 2024-02-14 | BIOTECHNOLOGY VALUE FUND L P | Aravive, Inc. | 5,664,238 | 7.1% | EDGAR |
| SC 13G/A | 2024-02-14 | BAKER BROS. ADVISORS LP | Aravive, Inc. | 3,863,568 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-09 | Artal International S.C.A. | Aravive, Inc. | 7,609,522 | 9.4% | EDGAR |
| SC 13G | 2023-02-14 | BAKER BROS. ADVISORS LP | Aravive, Inc. | 4,586,404 | 7.5% | EDGAR |
| SC 13G/A | 2023-02-13 | Artal International S.C.A. | Aravive, Inc. | 12,182,037 | 9.9% | EDGAR |
| SC 13D/A | 2022-12-28 | Zhang Eric | Aravive, Inc. | 2,029,634 | 3.4% | EDGAR |
| SC 13D/A | 2022-12-27 | Giaccia Amato | Aravive, Inc. | 1,725,244 | 2.9% | EDGAR |
| SC 13G | 2022-11-07 | BIOTECHNOLOGY VALUE FUND L P | Aravive, Inc. | 3,908,320 | 6.4% | EDGAR |
| SC 13D/A | 2022-11-03 | Eshelman Ventures, LLC | Aravive, Inc. | 26,378,105 | 43.5% | EDGAR |
| SC 13D/A | 2022-04-05 | ESHELMAN FREDRIC N | Aravive, Inc. | 10,071,985 | 33.9% | EDGAR |
| SC 13G/A | 2022-02-11 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 946,423 | 4.5% | EDGAR |
| SC 13D/A | 2022-01-06 | ESHELMAN FREDRIC N | Aravive, Inc. | 4,272,130 | 19.9% | EDGAR |
| SC 13D/A | 2021-04-15 | Tabibiazar Raymond | Aravive, Inc. | 1,606,511 | 7.9% | EDGAR |
| SC 13D/A | 2021-03-23 | Giaccia Amato | Aravive, Inc. | 1,178,312 | 5.9% | EDGAR |
| SC 13D/A | 2021-02-19 | ESHELMAN FREDRIC N | Aravive, Inc. | 3,806,098 | 19.6% | EDGAR |
| SC 13D/A | 2021-02-19 | Liu Qianye | Aravive, Inc. | 449,910 | 2.8% | EDGAR |
| SC 13G/A | 2021-02-16 | Artal International S.C.A. | Aravive, Inc. | 1,311,291 | 8.2% | EDGAR |
| SC 13D | 2020-04-16 | ESHELMAN FREDRIC N | Aravive, Inc. | 931,098 | 5.8% | EDGAR |
| SC 13G/A | 2020-02-13 | New Leaf Biopharma Opportunities II, L.P. | Aravive, Inc. | 946,423 | 6.3% | EDGAR |
| SC 13G | 2019-12-10 | Artal International S.C.A. | Aravive, Inc. | 1,350,000 | 9.0% | EDGAR |